By performing enrichment analysis of these DEGs, we further verified active lipid metabolism in HR-negative HER2-low breast cancers (Supplementary Fig. S5a, b, Source Data), which was further validated at the proteome level (Supplementary Fig. S5c–f). Here, ERBB2 is linked to breast carcinoma.